This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Inclusion Criteria: * ≥19 year old patients with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors * Lesions measured by tumor markers or by CT/MRI must be evaluable based on response evaluation criteria in solid tumors (RECIST) version 1.1. * Life expectancy ≥12 weeks * ECOG performance status ≤2 * Women of childbearing potential must have a negative pregnancy test outcome * Patients must provide written informed consent to voluntary participation in this study. Exclusion Criteria: * History of hypersensitivity reactions to any of the components of the investigational product or other drugs of the same class * Less than 4 weeks have elapsed since a major surgery and 2 weeks have elapsed since a minor surgery * New York Heart Association (NYHA) class ≥II congestive heart failure (CHF) * Persistent, clinically significant NCI-CTCAE v4.03 Grade ≥2 toxicities from the previous anticancer therapy * Severe infections or severe traumatic systemic disorders * Symptomatic or uncontrolled central nervous system (CNS) metastasis * Pregnant or lactating women or patients planning to become pregnant during the study * Participation in another clinical trial within 30 days prior to screening * Administration of antiplatelets or anticoagulants within 2 weeks prior to screening * Requiring continuous treatment with systemic NSAIDs or systemic corticosteroids * HIV or other severe diseases that warrant the exclusion from this study * Peritoneal and/or pleural fluid drainage within 28 days prior to screening * History of hemoptysis within 28 days prior to screening * Serious, untreated scar, active ulcer, or untreated fracture